Research programme: interferon beta gene therapy - Bayer HealthCare Pharmaceuticals

Drug Profile

Research programme: interferon beta gene therapy - Bayer HealthCare Pharmaceuticals

Latest Information Update: 24 Mar 2010

Price : $50

At a glance

  • Originator Berlex Biosciences
  • Developer Bayer HealthCare Pharmaceuticals
  • Class Gene therapies
  • Mechanism of Action Interferon beta stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No

Highest Development Phases

  • No development reported Multiple sclerosis

Most Recent Events

  • 10 Oct 2008 Preclinical development is ongoing in USA
  • 04 Apr 2007 Berlex is now called Bayer HealthCare Pharmaceuticals
  • 20 Jun 2005 Preclinical trials in Multiple sclerosis in USA (IM)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top